Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company is headquartered in San Diego, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-1.88M |
| EBITDA | $-17.13M |
| Operating Margin | 0.00% |
| Return on Equity | -159.30% |
| Return on Assets | -27.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.23 |
| Price-to-Book | 0.66 |
| Price-to-Sales (TTM) | 0.31 |
| EV/Revenue | 0.812 |
| EV/EBITDA | 2.38 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $34.03M |
| Float | $28.55M |
| % Insiders | 11.96% |
| % Institutions | 17.32% |
Volatility is currently expanding